ojrdrtОнкологический журнал: лучевая диагностика, лучевая терапияJournal of oncology: diagnostic radiology and radiotherapy2587-75932713-167XНЕКОММЕРЧЕСКОЕ ПАРТНЕРСТВО «ОБЩЕСТВО ИНТЕРВЕНЦИОННЫХ ОНКОРАДИОЛОГОВ»10.37174/2587-7593-2018-1-1-24-30ojrdrt-36Research ArticleЯДЕРНАЯ МЕДИЦИНАNUCLEAR MEDICINEПЭТ/КТ с 18F-фторхолином при рецидивах рака предстательной железы18F-fluorocholine PET/CT for Recurrences of Prostate CancerОджароваА. А.OdzharovaA. A.

Москва

Moscow

ДолгушинМ. Б.DolgushinM. B.

Москва

Moscow

МатвеевВ. Б.MatveevV. B.

Москва

Moscow

МихайловА. И.MihailovA. I.

Москва

Moscow

МещеряковаН. А.MeshcheryakovaN. A.

Москва

Moscow

mdnadya@gmail.comНевзоровД. И.NevzorovD. I.

Москва

Moscow

СоколовЕ. Н.SokolovE. N.

Москва

Moscow

Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава РФРоссияN.N. Blokhin National Medical Research Center of OncologyRussian Federation201830032018112430Copyright © Оджарова А.А., Долгушин М.Б., Матвеев В.Б., Михайлов А.И., Мещерякова Н.А., Невзоров Д.И., Соколов Е.Н., 20182018Оджарова А.А., Долгушин М.Б., Матвеев В.Б., Михайлов А.И., Мещерякова Н.А., Невзоров Д.И., Соколов Е.Н.Odzharova A.A., Dolgushin M.B., Matveev V.B., Mihailov A.I., Meshcheryakova N.A., Nevzorov D.I., Sokolov E.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncoradjournal.ru/jour/article/view/36

Позитронная эмиссионная томография с 18F-фторхолином, совмещенная с компьютерной томографией (ПЭТ/КТ), основанная на оценке биораспределения фосфатидилхолина, является эффективным методом диагностики при биохимических рецидивах рака предстательной железы (РПЖ). По результатам нашего исследования, основанном на анализе 79 наблюдений пациентов с биохимическим рецидивом РПЖ (уровень простатспецифического антигена в сыворотке крови 1,775 нг/мл), чувствительность двухэтапной ПЭТ/КТ с 18F-фторхолином составила 66,7 %, доверительный интервал 95 % (ДИ) 55,3–78,0, при специфичности 80 % (ДИ 44,9–100,0), общая точность метода колебалась от 56,7 до 78,5 %. Полученные результаты свидетельствуют о целесообразности применения ПЭТ/КТ с 18F-фторхолином в режиме двухэтапного сканирования при биохимических рецидивах РПЖ.

PET/CT with 18F-fluorocholine, based on the assessment of phosphatidylcholine biodistribution, is an effective method in the diagnosis of biochemical recurrence of prostate cancer. According to results of our study on 79 patients (PSA level 1.775 ng/mL), the sensitivity of two-stage PET/CT with 18F-fluorocholine was 66.7 % (CI 55.3–78.0 %), and specificity – 80 % (CI 44.9–100.0 %), the overall accuracy of the method ranged from 56.7 to 78.5 %. The results show the feasibility of two-staged PET/CT with 18F-fluorocholine in biochemical recurrence of prostate cancer.

ПЭТ/КТрак предстательной железы18F-фторхолинбиохимический рецидиврадикальная простатэктомияPET/CTprostate cancer18F-fluorocholinebiochemical recurrenceprostatectomyReferencesАксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2008 г. // Вестник РОНЦ им. Н.Н. Блохина РАМН. 2010. № 21.Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2008 г. // Вестник РОНЦ им. Н.Н. Блохина РАМН. 2010. № 21.Злокачественные новообразования в России в 2010 году (заболеваемость и смертность). Под. ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. – М.: ФГУ «МНИОИ им. П.А. Герцена Росмедтехнологий». 2011. 256 с.Злокачественные новообразования в России в 2010 году (заболеваемость и смертность). Под. ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. – М.: ФГУ «МНИОИ им. П.А. Герцена Росмедтехнологий». 2011. 256 с.Ferlay J., Soerjomataram I., Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 // Int. J. Cancer. 2014.Ferlay J., Soerjomataram I., Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 // Int. J. Cancer. 2014.Budiharto T., Joniau S., Lerut E. et al. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases // Eur. Urol. 2011. Vol. 60. P. 125–130.Budiharto T., Joniau S., Lerut E. et al. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases // Eur. Urol. 2011. Vol. 60. P. 125–130.Etzioni R., Cha R., Feuer E.J., Davidov O. Asymptomaticincidence and duration of prostate cancer // Amer. J. Epidemiol. 1998. Vol. 148. № 8. P. 775–785.Etzioni R., Cha R., Feuer E.J., Davidov O. Asymptomaticincidence and duration of prostate cancer // Amer. J. Epidemiol. 1998. Vol. 148. № 8. P. 775–785.Cimitan M., Bortolus R., Morassut S. et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients // Eur. J. Nucl. Med. 2006. Vol. 33. № 12. P. 1387–1398.Cimitan M., Bortolus R., Morassut S. et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients // Eur. J. Nucl. Med. 2006. Vol. 33. № 12. P. 1387–1398.Hara T., Kosaka N., Kishi H. PET imaging of prostate cancer using carbon-11-choline / // J. Nucl. Med. 1998. Vol. 39. № 6. P. 990–995.Hara T., Kosaka N., Kishi H. PET imaging of prostate cancer using carbon-11-choline / // J. Nucl. Med. 1998. Vol. 39. № 6. P. 990–995.Basch E. et al. Systemic therapy in men with metastatic castrationresistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline // J. Clin. Oncol. 2014. Vol. 32. №. 30. P. 3436–3448.Basch E. et al. Systemic therapy in men with metastatic castrationresistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline // J. Clin. Oncol. 2014. Vol. 32. №. 30. P. 3436–3448.Котляров П.М. Лучевая диагностика рака предстательной железы // Росс. онкол. журнал. 2008. № 2. C. 49–53.Котляров П.М. Лучевая диагностика рака предстательной железы // Росс. онкол. журнал. 2008. № 2. C. 49–53.Carter H.B., Pearson J.D., Metter E.J. et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease // JAMA. 1992. Vol. 267. № 16. P. 2215– 2020.Carter H.B., Pearson J.D., Metter E.J. et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease // JAMA. 1992. Vol. 267. № 16. P. 2215– 2020.Leventis K., Shariat S.F., Slawin K.M. Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings // Radiology. 2001. Vol. 219. № 2. P. 432– 439.Leventis K., Shariat S.F., Slawin K.M. Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings // Radiology. 2001. Vol. 219. № 2. P. 432– 439.Hudson M.A., Bahnson R.R., Catalona W.J. Clinical use of PSA in patients with prostate cancer // J. Urol. 1989. Vol. 142. № 4. P. 1011–1017.Hudson M.A., Bahnson R.R., Catalona W.J. Clinical use of PSA in patients with prostate cancer // J. Urol. 1989. Vol. 142. № 4. P. 1011–1017.Mottet N., Bastian P.J., Bellmunt J. et al. EAU guidelines on prostate cancer. Update April 2014. European Association of Urology. http://www.uroweb.org/guidelines/online-guidelines/. Accessed 25 April 2014.Mottet N., Bastian P.J., Bellmunt J. et al. EAU guidelines on prostate cancer. Update April 2014. European Association of Urology. http://www.uroweb.org/guidelines/online-guidelines/. Accessed 25 April 2014.Arlen P.M., Bianco F., Dahut W.L. et al. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time // J. Urol. 2012. Vol. 179. № 6. P. 2181–2185.Arlen P.M., Bianco F., Dahut W.L. et al. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time // J. Urol. 2012. Vol. 179. № 6. P. 2181–2185.Schmid D.T., John H., Zweifel R. et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience // Radiology. 2005. Vol. 235. P. 623–628.Schmid D.T., John H., Zweifel R. et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience // Radiology. 2005. Vol. 235. P. 623–628.Schmid H.-P., McNeal J.E., Stamey T.A. Observations on the doubling time of prostate cancer. The use of serial prostatespecific antigen in patients with untreated disease as a measure of increasing cancer volume // Cancer. 1993. Vol. 71. № 6. P. 2031–2040.Schmid H.-P., McNeal J.E., Stamey T.A. Observations on the doubling time of prostate cancer. The use of serial prostatespecific antigen in patients with untreated disease as a measure of increasing cancer volume // Cancer. 1993. Vol. 71. № 6. P. 2031–2040.Sanz G., Rioja J., Zudaire J. et al. PET and prostate cancer // World J. Urol. 2004. Vol. 22. P. 351–352.Sanz G., Rioja J., Zudaire J. et al. PET and prostate cancer // World J. Urol. 2004. Vol. 22. P. 351–352.Theodorescu D., Broder S.R., Boyd J.C. et al. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate // J. Urol. 1997. Vol. 158. № 1. P. 131–137.Theodorescu D., Broder S.R., Boyd J.C. et al. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate // J. Urol. 1997. Vol. 158. № 1. P. 131–137.MacGrogan D., Bookstein R. Tumour suppressor genes in prostate cancer // Semin. Cancer Biol. 1997. Vol. 8. № 1. P. 11–19.MacGrogan D., Bookstein R. Tumour suppressor genes in prostate cancer // Semin. Cancer Biol. 1997. Vol. 8. № 1. P. 11–19.Karam J.A., Mason R.P., Koeneman K.S. et al. Molecular imaging in prostate cancer // J. Cell Biochem. 2003. Vol. 90. P. 473–483.Karam J.A., Mason R.P., Koeneman K.S. et al. Molecular imaging in prostate cancer // J. Cell Biochem. 2003. Vol. 90. P. 473–483.Turkbey B., Pinto P.A., Mani H. et al. Prostate cancer: value of multiparametric MR imaging at 3T for detection – histopathologic correlation // Radiology. 2010. Vol. 255. № 1. P. 89–99.Turkbey B., Pinto P.A., Mani H. et al. Prostate cancer: value of multiparametric MR imaging at 3T for detection – histopathologic correlation // Radiology. 2010. Vol. 255. № 1. P. 89–99.Turkbey B., Mani H., Shah V. et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds // J. Urol. 2011. Vol. 186. № 5. P. 1818–1824.Turkbey B., Mani H., Shah V. et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds // J. Urol. 2011. Vol. 186. № 5. P. 1818–1824.Selnaes K.M., Heerschap A., Jensen L.R. et al. Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3T: unbiased cancer identification by matching to histopathology // Invest. Radiol. 2012. Vol. 47. № 11. P. 624–633.Selnaes K.M., Heerschap A., Jensen L.R. et al. Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3T: unbiased cancer identification by matching to histopathology // Invest. Radiol. 2012. Vol. 47. № 11. P. 624–633.Bratan F., Niaf E., Melodelima C. et al. Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study // Eur. Radiol. 2013. Vol. 23. № 7. P. 2019–29Bratan F., Niaf E., Melodelima C. et al. Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study // Eur. Radiol. 2013. Vol. 23. № 7. P. 2019–29Hoeks C.M., Schouten M.G., Bomers J.G. et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers // Eur. Urol. 2012. Vol. 62. № 5. P. 902–909.Hoeks C.M., Schouten M.G., Bomers J.G. et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers // Eur. Urol. 2012. Vol. 62. № 5. P. 902–909.Puech P., Rouviere O., Renard-Penna R. et al. Prostate cancer diagnosis: multiparametric mr-targeted biopsy with cognitive and transrectal US-MR Fusion Guidance versus Systematic Biopsy-Prospective Multicenter Study // Radiology. 2013. Vol. 268. № 2. P. 461–469.Puech P., Rouviere O., Renard-Penna R. et al. Prostate cancer diagnosis: multiparametric mr-targeted biopsy with cognitive and transrectal US-MR Fusion Guidance versus Systematic Biopsy-Prospective Multicenter Study // Radiology. 2013. Vol. 268. № 2. P. 461–469.Apolo A.B., Pandit-Taskar N., Morris M.J. Novel tracers and their development for the imaging of metastatic prostate cancer // J. Nucl. Med. 2008. Vol. 49. P. 2031–2041.Apolo A.B., Pandit-Taskar N., Morris M.J. Novel tracers and their development for the imaging of metastatic prostate cancer // J. Nucl. Med. 2008. Vol. 49. P. 2031–2041.Husarik D.B., Miralbell R., Dubs M. et al. Evaluation of [(18)F]choline PET/CT for staging and restaging of prostate cancer // Eur. J. Nucl. Med. Mol. Imaging. 2008. Vol. 35. P. 253–263.Husarik D.B., Miralbell R., Dubs M. et al. Evaluation of [(18)F]choline PET/CT for staging and restaging of prostate cancer // Eur. J. Nucl. Med. Mol. Imaging. 2008. Vol. 35. P. 253–263.Effert P.J., Bares R., Handt S et al. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18F-labeled deoxyglucose // J. Urol. 1996. Vol. 155. P. 994–998.Effert P.J., Bares R., Handt S et al. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18F-labeled deoxyglucose // J. Urol. 1996. Vol. 155. P. 994–998.Wetter A., Lipponer C., Nensa F. et al. Evaluation of the PET component of simultaneous [18F]choline PET/MRI in prostate cancer: comparison with [18F]choline PET/CT // Eur. J. Nucl. Med. Mol. Imaging. 2014. Vol. 41. № 1. P. 79–88.Wetter A., Lipponer C., Nensa F. et al. Evaluation of the PET component of simultaneous [18F]choline PET/MRI in prostate cancer: comparison with [18F]choline PET/CT // Eur. J. Nucl. Med. Mol. Imaging. 2014. Vol. 41. № 1. P. 79–88.Wu L.M., Xu J.R., Gu H.Y. et al. Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy // Clin. Oncol. 2013. Vol. 25. № 4. P. 252–264.Wu L.M., Xu J.R., Gu H.Y. et al. Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy // Clin. Oncol. 2013. Vol. 25. № 4. P. 252–264.Джужа Д.А. Позитронная эмиссионная томография в онкоурологии // Лучевая диагностика и терапия. 2013. № 2/3. С. 67–75.Джужа Д.А. Позитронная эмиссионная томография в онкоурологии // Лучевая диагностика и терапия. 2013. № 2/3. С. 67–75.Mease R.C. Radionuclide based imaging of prostate cancer // Curr. Top Med. Chem. 2010. Vol. 10. P. 1600–1616.Mease R.C. Radionuclide based imaging of prostate cancer // Curr. Top Med. Chem. 2010. Vol. 10. P. 1600–1616.Heidenreich J., Bellmunt M., Bolla K. et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease // Eur. Urol. 2011. Vol. 59. № 1. P. 61– 71.Heidenreich J., Bellmunt M., Bolla K. et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease // Eur. Urol. 2011. Vol. 59. № 1. P. 61– 71.Emonds K.M., Swinnen J.V., Mortelmans L., Mottaghy F.M. Molecular imaging of prostate cancer // Methods. 2009. Vol. 48. P. 193–199.Emonds K.M., Swinnen J.V., Mortelmans L., Mottaghy F.M. Molecular imaging of prostate cancer // Methods. 2009. Vol. 48. P. 193–199.Gutman F., Afl alo-Hazan V., Kerrou K. et al. 18F-choline PET/ CT for initial staging of advanced prostate cancer // AJR. 2006. Vol. 187. P. W618–W621.Gutman F., Afl alo-Hazan V., Kerrou K. et al. 18F-choline PET/ CT for initial staging of advanced prostate cancer // AJR. 2006. Vol. 187. P. W618–W621.Schillaci O., Calabria F., Tavolozza M. et al. 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer // Nucl. Med. Commun. 2010. Vol. 31. P. 39–44.Schillaci O., Calabria F., Tavolozza M. et al. 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer // Nucl. Med. Commun. 2010. Vol. 31. P. 39–44.Sutinen E., Nurmi M., Roivainen A. et al. Kinetics of 11C-choline uptake in prostate cancer: a PET study // Eur. J. Nucl. Med. Mol. Imaging. 2004. Vol. 31. P. 317–324.Sutinen E., Nurmi M., Roivainen A. et al. Kinetics of 11C-choline uptake in prostate cancer: a PET study // Eur. J. Nucl. Med. Mol. Imaging. 2004. Vol. 31. P. 317–324.Chiti A. The rising PET: the increasing use of choline PET/CT in prostate cancer // Eur. J. Nucl. Med. 2011. Vol. 38. P. 53–54.Chiti A. The rising PET: the increasing use of choline PET/CT in prostate cancer // Eur. J. Nucl. Med. 2011. Vol. 38. P. 53–54.Greco C., Cascini G. L., Tamburini O. Is there a role for positron emission tomography imaging in the early evaluation of prostate cancer relapse? // Prostate Cancer and Prostatic Diseases. 2008. Vol. 11. P. 121–128.Greco C., Cascini G. L., Tamburini O. Is there a role for positron emission tomography imaging in the early evaluation of prostate cancer relapse? // Prostate Cancer and Prostatic Diseases. 2008. Vol. 11. P. 121–128.Piccardo A., Paparo F., Picazzo R.et al. Value of fused 18F-cholinePET/MRI to evaluate prostate cancer relapse in patients showing biochemical recurrence after EBRT: Preliminary results // BioMed. Res. Intern. Article ID 103718, 9 pages, 2014. doi:10.1155/2014/103718Piccardo A., Paparo F., Picazzo R.et al. Value of fused 18F-cholinePET/MRI to evaluate prostate cancer relapse in patients showing biochemical recurrence after EBRT: Preliminary results // BioMed. Res. Intern. Article ID 103718, 9 pages, 2014. doi:10.1155/2014/103718Beheshti M., Langsteger W., Fogelman I. Prostate cancer: role of SPECT and PET in imaging bone metastases // Semin. Nucl. Med. 2015. Vol. 48. P. 73–79.Beheshti M., Langsteger W., Fogelman I. Prostate cancer: role of SPECT and PET in imaging bone metastases // Semin. Nucl. Med. 2015. Vol. 48. P. 73–79.Beheshti M., Imamovic L., Broiger G. et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients // Radiology. 2010. Vol. 254. P. 925–933Beheshti M., Imamovic L., Broiger G. et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients // Radiology. 2010. Vol. 254. P. 925–933Tilki D., Reich O., Graser A. et al. 18F-fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent // Eur. Urol. 2013. Vol. 63. P. 792–796.Tilki D., Reich O., Graser A. et al. 18F-fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent // Eur. Urol. 2013. Vol. 63. P. 792–796.Kwee S. A. et al. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET // J. Nucl. Med. 2006. Vol. 47. № 2. P. 262–269.Kwee S. A. et al. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET // J. Nucl. Med. 2006. Vol. 47. № 2. P. 262–269.O’Brien M.F., Cronin A.M., Fearn P.A. et al. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy // J. Clin. Oncol. 2009. Vol. 27. № 22. P. 3591–3597.O’Brien M.F., Cronin A.M., Fearn P.A. et al. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy // J. Clin. Oncol. 2009. Vol. 27. № 22. P. 3591–3597.Zeisel S.H. Dietary choline: biochemistry, physiology, and pharmacology // Ann. Rev. Nutr. 1981. Vol. 1. P. 95–121.Zeisel S.H. Dietary choline: biochemistry, physiology, and pharmacology // Ann. Rev. Nutr. 1981. Vol. 1. P. 95–121.Carolan P., Hunt C., McConnell D. et al. Radiation exposure reduction to PET technologists with the use of an automated dosage infusion system // J. Nucl. Med. Meeting Abstracts. 2012. Vol. 53. P. 2185.Carolan P., Hunt C., McConnell D. et al. Radiation exposure reduction to PET technologists with the use of an automated dosage infusion system // J. Nucl. Med. Meeting Abstracts. 2012. Vol. 53. P. 2185.Massaro A. et al. Optimising 18F-choline PET/CT acquisition protocol in prostate cancer patients // N. Amer. J. Med. Sci. 2012. Vol. 4. № 9. P. 416–424.Massaro A. et al. Optimising 18F-choline PET/CT acquisition protocol in prostate cancer patients // N. Amer. J. Med. Sci. 2012. Vol. 4. № 9. P. 416–424.Vali R., Loidl W., Pirich C. et al. Imaging of prostate cancer with PET/CT using 18F-Fluorocholine // Amer. J. Nucl. Med. Mol. Imaging. 2015. Vol. 5. № 2. P. 96–108.Vali R., Loidl W., Pirich C. et al. Imaging of prostate cancer with PET/CT using 18F-Fluorocholine // Amer. J. Nucl. Med. Mol. Imaging. 2015. Vol. 5. № 2. P. 96–108.Beauregard J.-M., Pouliot F. New developments in the imaging of metastatic prostate cancer // Curr. Opin. Support. Palliat. Care. 2014. Vol. 8. № 3. P. 265–270.Beauregard J.-M., Pouliot F. New developments in the imaging of metastatic prostate cancer // Curr. Opin. Support. Palliat. Care. 2014. Vol. 8. № 3. P. 265–270.Evangelista L., Cervino A.R., Guttilla A. et al. 18F-fluoromethylcholine or 18F-fluoroethylcholine PET for prostate cancer imaging: which is better? A literature revision // Nucl. Med. Biol. 2015. Vol. 42. № 4. P. 340–348.Evangelista L., Cervino A.R., Guttilla A. et al. 18F-fluoromethylcholine or 18F-fluoroethylcholine PET for prostate cancer imaging: which is better? A literature revision // Nucl. Med. Biol. 2015. Vol. 42. № 4. P. 340–348.Beheshti M., Haroon A., Bomanji J.B., Langsteger W. Fluorocholine PET/computed tomography: physiologic uptake, benign findings, and pitfalls // PET Clin. 2014. Vol. 9. № 3. P. 299–306.Beheshti M., Haroon A., Bomanji J.B., Langsteger W. Fluorocholine PET/computed tomography: physiologic uptake, benign findings, and pitfalls // PET Clin. 2014. Vol. 9. № 3. P. 299–306.Beauregard J.-M., Beaulieu A. How we read FCH-PET/CT for prostate cancer? // Cancer Imaging. 2016. Vol. 16. № 1. P. 44–51.Beauregard J.-M., Beaulieu A. How we read FCH-PET/CT for prostate cancer? // Cancer Imaging. 2016. Vol. 16. № 1. P. 44–51.Agarwal N., Sonpavde G., Sternberg C.N. Novel molecular targets for the therapy of castrationresistant prostate cancer // Eur. Urol. 2012. Vol. 61. P. 950–960.Agarwal N., Sonpavde G., Sternberg C.N. Novel molecular targets for the therapy of castrationresistant prostate cancer // Eur. Urol. 2012. Vol. 61. P. 950–960.Holland-Letz T., Giesel F.L., Kratochwil C., Haufe S. PET imaging with a [68Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: Biodistribution in humans and first evaluation of tumour lesions // Eur. J. Nucl. Med. Mol. Imaging. 2013. Vol. 40. P. 486–495.Holland-Letz T., Giesel F.L., Kratochwil C., Haufe S. PET imaging with a [68Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: Biodistribution in humans and first evaluation of tumour lesions // Eur. J. Nucl. Med. Mol. Imaging. 2013. Vol. 40. P. 486–495.Hong H., Zhang Y., Sun J., Cai W. Positron emission tomography imaging of prostate cancer // Amino Acids. 2010. Vol. 39. P. 11– 27.Hong H., Zhang Y., Sun J., Cai W. Positron emission tomography imaging of prostate cancer // Amino Acids. 2010. Vol. 39. P. 11– 27.Rauscher I., Maurer T., Fendler W.P et al. 68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report // Cancer Imaging. 2016. Vol. 16. P. 14. doi:10.1186/s40644-016-0072-6.Rauscher I., Maurer T., Fendler W.P et al. 68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report // Cancer Imaging. 2016. Vol. 16. P. 14. doi:10.1186/s40644-016-0072-6.

The authors declare that there are no conflicts of interest present.